title: Response to hormonal treatment of young females with primary or very premature ovarian failure.
abstract: The aim of this study was to evaluate the impact of hormone treatment (HT) on several endocrinologic, metabolic and bone parameters in young women with primary or very premature ovarian failure. The study included 40 phenotypically females of 14-20 years old with primary or secondary amenorrhoea and female external genitalia. Study subjects were categorised in three groups: Group A included 12 subjects with Turner syndrome, Group B included 19 subjects with Swyer syndrome and Group C included 9 subjects with very premature ovarian failure. HT was administered for 24 months and included conjugated oestrogens and medroxyprogesterone acetate. In all groups, HT provided a beneficial hormonal profile and resulted in safe and adequate serum oestrogens levels. In Group A, no adverse effects on metabolic or coagulation parameters were noted; significant increases in high-density lipoprotein cholesterol (HDL) levels and bone density were observed. Similar positive effects of HT were observed in Group B. Finally, in Group C, no adverse effects of HT were noted, but the favourable increase in HDL was absent; bone density kept significantly increasing until the 12-month evaluation. In conclusion, the administration of HT is remarkably beneficial for young women with primary or very premature ovarian failure.
authors.affiliation: Second Department of Obstetrics and Gynecology, University of Athens, Aretaieion Hospital, Athens, Greece. vpapagianni@yahoo.com
authors.forename: Vassiliki
authors.initials: V
authors.lastname: Papagianni
authors.forename: Efthimios
authors.initials: E
authors.lastname: Deligeoroglou
authors.forename: Evangelos
authors.initials: E
authors.lastname: Makrakis
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Botsis
authors.forename: George
authors.initials: G
authors.lastname: Creatsas
mesh_terms: D000293:Adolescent; D000568:Amenorrhea / Q000097:blood / Q000188:drug therapy; D015519:Bone Density / Q000187:drug effects*; D008076:Cholesterol, HDL / Q000097:blood* / Q000187:drug effects; D004967:Estrogens / Q000097:blood / Q000627:therapeutic use; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use; D005260:Female; D006061:Gonadal Dysgenesis, 46,XY / Q000188:drug therapy; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use; D016649:Primary Ovarian Insufficiency / Q000097:blood / Q000188:drug therapy*; D014424:Turner Syndrome / Q000188:drug therapy; D055815:Young Adult
chemical_list: D008076:Cholesterol, HDL; D004967:Estrogens; D004966:Estrogens, Conjugated (USP); D017258:Medroxyprogesterone Acetate